LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (the "Company†) (Nasdaq: SVRA), a clinical- stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has received the Day 74 Letter from the FDA which indicated that an Advisory Committee meeting is not planned for the MOLBREEVI Biologics License Application (BLA) and the review is ongoing with a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. Additionally, the Company recently submitt. ...

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - Trinity One Metals Ltd. (TSXV: TOM) (the "Company" or "Trinity One") is pleased to announce the closing of its previously announced non-brokered private placement offerings. The Company issued an aggregate of 26,700,000 units (the "Units") at a price of $0.20 per Unit for gross proceeds of $5,340,000 across both offerings. Under the Listed Issuer Financing Exemption offering (the "LIFE Offering"), the Company issued 16,700,000 Units for gross p ...

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...

HOUSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Powell Industries, Inc. (NASDAQ: POWL) announced today that its Board of Directors has approved a three-for-one forward stock split of the Company's common stock. The Board of Directors also approved a proportionate increase in the number of authorized shares of common stock to accommodate the stock split. The split will be effected through an amendment to the Company's Amended and Restated Certificate of Incorporation. Each shareholder of record as of the close o ...

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - March 6, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Day One Biopharmaceuticals, Inc. ("Day One" or the "Company") (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Servier for $21.50 per share in an all-cash transaction, representing a total equity value of approximately $2.5 billion. The ...

BEDFORD, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has approved PYLARIFY TruVu (piflufolastat F 18) injection, a new formulation of its F 18 prostate-specific membrane antigen (PSMA) imaging agent. PYLARIFY TruVu is indicated for positron emis ...

Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a global leader in life science research tools, today announced that its board of directors approved the Company's 1-for-10 reverse stock split (the "Reverse Split") of the Company's common stock, par value $0.01 per share. The Reverse Split was approved by the stoc ...

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (NASDAQ: HYFT), a bio- native AI company, today announced B Cell Llamaâ"¢, a platform for the discovery of VHH nanobodies: the single-domain antibody fragments increasingly recognized as the ideal molecular building blocks for bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies. Bispecific antibody sales alone are projected to reach US$50 billion by 2030, with the broader cell therapy market adding tens of billions ...

Core Insights - Korn Ferry is preparing to release its quarterly earnings on March 9, 2026, with Wall Street estimating earnings per share (EPS) at $1.22 and projected revenue at approximately $695.1 million [1][6] Financial Metrics - The company has a price-to-earnings (P/E) ratio of approximately 12.6, indicating moderate market valuation of its earnings [3][6] - Korn Ferry's price-to-sales ratio is about 1.17, reflecting investor willingness to pay per dollar of sales [3][6] - The enterprise value to sales ratio stands at around 1.10, showing the company's total valuation relative to its sales [3] - An enterprise value to operating cash flow ratio of approximately 8.83 suggests efficient cash flow generation relative to its valuation [4] - The earnings yield is about 7.94%, providing a perspective on return on investment [4] - The company maintains a low debt-to-equity ratio of roughly 0.28, indicating prudent financial management [4] Financial Health - Korn Ferry's current ratio is approximately 2.14, highlighting strong short-term financial health and the ability to meet short-term obligations [5][6] Investor Engagement - The earnings report will be released before market opening, followed by a live webcast at 12:00 pm EDT, providing detailed insights into the company's performance [2][6]

CLASS PERIOD: March 4, 2025 to November 12, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Paysafe's ecommerce business had significant exposure to a single high risk client; (2) as a result, the Company's credit loss reserves and/or write-offs were understated; (3) Paysafe had an undisclosed issue with higher risk merchant category codes, making its client services difficult to bank; ( ...